M. Gore

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

G.J. Creemers, Giorgio Bolis, M. Gore et al. · Journal of Clinical Oncology · 1996 · 386 citations

EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont Am, Stefan Suciu, Mario Santinami et al. · Research Explorer (The University of Manchester) · 2008 · 111 citations

Surgical Oncology, Eortc Melanoma Group, Medicine +9

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily

Philip Savage, Vicki L. Horton, J. Moore et al. · British Journal of Cancer · 1996 · 107 citations · Full text

Immunodeficiencies, Immunology, Oral Interferon Inducer +2

Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)

Mark J. Ratain, K. T. Flaherty, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 107 citations

Urology, Phase Ii, Genitourinary Cancer +14

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

Helmout Modjtahedi, Tamas Hickish, Margery Nicolson et al. · British Journal of Cancer · 1996 · 102 citations · Full text

Malignant Disease, Medicine, Immunology +10